Placebo/rhASB [clinicaltrials_resource:NCT00104234/group/P2]
Patients received placebo in the double-blind study (ASB-03-05, NCT00067470)then received rhASB in the extension study (ASB-03-06).
participant flow for clinicaltrials:NCT00104234 [clinicaltrials_resource:39032299962828e71bc3ada52d7c7a39]participant counts in P2 for milestone 2 of NCT00104234 [clinicaltrials_resource:NCT00104234/milestone/1/p/2]participant counts in P2 for milestone 3 of NCT00104234 [clinicaltrials_resource:NCT00104234/milestone/2/p/2]participant counts in P2 for milestone 4 of NCT00104234 [clinicaltrials_resource:NCT00104234/milestone/3/p/2]
group [clinicaltrials_vocabulary:group]
Placebo/rhASB [clinicaltrials_resource:NCT00104234/group/P2]
Patients received placebo in the double-blind study (ASB-03-05, NCT00067470)then received rhASB in the extension study (ASB-03-06).
Bio2RDF identifier
NCT00104234/group/P2
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:NCT00104234/group/P2
group id [clinicaltrials_vocabulary:group-id]
description
Patients received placebo in t ...... e extension study (ASB-03-06).
@en
identifier
clinicaltrials_resource:NCT00104234/group/P2
title
Placebo/rhASB
@en
type
label
Placebo/rhASB [clinicaltrials_resource:NCT00104234/group/P2]
@en